Skip to content
SPY$715.87down −1.96%
Nasdaq$645.04down −2.19%
Nvidia$145.98down −3.30%
SpaceX$138.43down −3.53%
BTC$61,334.00down −2.16%
Gold$3,540.71down −5.30%
Silver$42.30down −8.22%
Brent oil$92.50up +0.37%
DXY103.72down −0.07%
EUR/USD1.0964down −0.09%
USD/JPY159.30down −0.29%
2Y yield4.76%down −4 bp
5Y yield4.86%down −3 bp
10Y yield5.04%down −3 bp

Search FinPrism

Companies · · 3 min read

Editor: Bohdan S.

Pfizer raises 2026 outlook as Eliquis and newer drugs offset Covid slide

Pfizer beat third-quarter forecasts and lifted its full-year sales and profit ranges, as newer medicines and its blood thinner Eliquis made up for shrinking Covid revenue. It also confirmed a permanent CFO.

Pfizer raises 2026 outlook as Eliquis and newer drugs offset Covid slide

The short answer

Pfizer lifted its 2026 guidance to $62 billion to $64 billion in revenue and $2.95 to $3.05 in adjusted earnings per share after a third quarter that beat analyst forecasts, the company said. Newer and acquired products grew 32%, offsetting falling Covid sales, a shift the Financial Times (FT) also highlighted.

What happened

Pfizer posted third-quarter revenue of $16.6 billion on Tuesday, roughly unchanged from a year earlier, according to its results release. Adjusted earnings came to 87 cents a share. Analysts polled by LSEG had expected 73 cents and $15.87 billion in sales, CNBC reported. The drugmaker now sees full-year revenue of $62 billion to $64 billion, up from $60.5 billion to $62.5 billion, and adjusted earnings of $2.95 to $3.05 a share, up from $2.80 to $3.00. The Financial Times (FT) reported that sales of non-Covid medicines rose 7%. Pfizer also named Cecile Guegan, interim finance chief since August, as its permanent CFO from November 1.

What it means

The quarter shows Pfizer's mix of business changing. Excluding its Covid vaccine Comirnaty and its antiviral pill Paxlovid, revenue grew 7% once currency swings are stripped out, the company said, and products it has launched or bought recently grew 32% on the same basis. That group includes the bladder cancer drug Padcev, the RSV vaccine Abrysvo, the pneumococcal shot Prevnar 20 and the lung cancer pill Lorbrena, according to CNBC. Headline sales stayed flat because Covid revenue kept shrinking, which ate up most of the growth elsewhere.

Eliquis, Pfizer's blood thinner, did a lot of the heavy lifting. CNBC reported its sales rose 25% to $2.52 billion, ahead of the $2.40 billion StreetAccount analysts had penciled in, while Padcev brought in $720 million against expectations of $658 million. Even the Covid franchise came in a little better than feared: the vaccine sold $808 million and Paxlovid $449 million, both above estimates despite steep declines.

The raised outlook is notable because it already absorbs a one-time hit. Pfizer booked a $650 million charge in the quarter, worth about 10 cents a share, tied to its licensing deal with Chinese cancer drug developer Innovent Biologics, yet still lifted its profit range. On a reported basis, which includes items such as restructuring and acquisition-related costs, net income fell to $3.24 billion, or 56 cents a share, from $3.54 billion a year before. Adjusted figures leave those items out, which is why the two numbers differ so much.

Behind all this is a longer turnaround. With pandemic demand fading and generic competition looming over some of its biggest sellers, Pfizer has leaned on acquisitions, new cancer treatments and a push into obesity drugs through its purchase of Metsera, CNBC noted. It is also cutting costs, aiming for about $9.7 billion in net savings through 2029. Even at the bottom of the new range, full-year sales would be roughly flat or slightly lower than the $62.6 billion it booked in 2025, so the story is stabilization rather than a return to rapid growth.

The bull case

Optimists would point to a clean beat on both sales and profit, and a guidance raise that holds up even after a $650 million charge. Newer products growing by about a third suggest Pfizer's pipeline and deals are starting to pay off, while savings targets of roughly $9.7 billion could help protect margins. A finance chief promoted from within may also offer continuity as the turnaround continues.

The bear case

Skeptics would note that total revenue is still flat and that the low end of the new range implies sales no higher than in 2025. Reported earnings per share slipped to 56 cents from 62 cents, and much of the strength relies on Eliquis at a time when generic rivals threaten some of Pfizer's biggest sellers. Sales of Prevnar also declined, the company said. The obesity bet through Metsera and recent licensing deals are expensive and unproven, so the payoff from today's spending may take years.

Why it matters

For investors

The results put large US drugmakers and health care funds in focus, since they show how much newer medicines can replace fading pandemic revenue. Investors may watch whether the higher guidance holds through the rest of the year.

The wider context

Anyone holding Pfizer directly or through a broad stock fund has a stake in whether its newer drugs can keep replacing pandemic income. The quarter is a reminder that big companies often rebuild slowly after a boom ends.

Market impact

Asset (ticker)Possible moveTimeframeWhy
Pfizer (PFE) ↑ Up Short term Quarterly results beat forecasts and the company raised its full-year revenue and profit guidance.
Health Care Select Sector SPDR Fund (XLV) ↔ Unclear Short term One large drugmaker's beat helps sentiment but is unlikely to move the whole sector alone.

The FinPrism newsroom's view of how these figures could move, as of . It is general news commentary, not a recommendation to buy, sell or hold anything.

Frequently asked questions

Why did Pfizer raise its 2026 guidance?

Pfizer pointed to strong results so far this year. Third-quarter sales and adjusted profit beat analyst estimates, helped by Eliquis and newer drugs such as Padcev, so the company lifted its full-year revenue range to $62 billion to $64 billion and adjusted earnings to $2.95 to $3.05 a share.

How much did Pfizer earn in the third quarter of 2026?

Pfizer reported adjusted earnings of 87 cents a share on revenue of $16.6 billion, both ahead of forecasts, according to CNBC and the company. Reported net income was $3.24 billion, or 56 cents a share, down from $3.54 billion a year earlier, partly because of a $650 million licensing charge.

Who is Pfizer's new CFO?

Cecile Guegan became Pfizer's chief financial officer on November 1, 2026, after serving in the role on an interim basis since August. She has worked in finance roles at the company for about two decades. She replaced Dave Denton, who left to become finance chief at Nike, CNBC reported.

Sources: Pfizer company releases (Stock Titan), CNBC, Financial Times

How this was made: written with AI assistance from the sources listed above, following our editorial standards.

Back to the latest